You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An innovative in situ cell reprogramming technology for cancer treatment

    SBC: QURGEN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We invented an innovative protein induced Pluripotent Stem Cells (piPSCs) technology that generates piPSCs from normal fibroblast and cancer cells within 1-week with 90 4% conversion efficiency. Such high conversion efficiency enables us to pioneer an in situ cell reprogramming technology within the cancers of cancer-bearing animals. Instead of generating iPSCs ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Accurate Prostate Cancer Diagnosis for Active Surveillance Patients Using a Novel

    SBC: ProDevice Medical Supplies and Equipment LLC            Topic: NCI

    Project Abstract Active surveillance (AS) is becoming more accepted as a reasonable treatment option for men with low-risk prostate cancer (i.e. Gleason score 6, clinical stage T2a, PSA lt 10). Many AS protocols at major institutions call for a prostate saturation biopsy after initial diagnosis to confirm that the patient has no areas of higher-risk prostate cancer. For most patients who underwent ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. CMV Vectored Herpes Simplex Vaccine

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), the causative agent of genital herpes. HSV-2 is widely prevalent in the population causing recurrent genital lesions and significantly increasing the risk for other sexually transmitted diseases such a ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Mucins in the Diagnosis and Prognosis of Pancreatic Diseases

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Due to its asymptomatic nature and lack of methods for early detection, gt 80% of pancreatic cancer (PC) patients present with an unresectable primary tumor with distant metastasis at the time of diagnosis. While the overall 5 year survival rate of pancreatic cancer is dismal, significantly better outcomes have been reported for smaller tumors detected at an e ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Novel scFv-Antibody Fusion siRNA Carrier Protein for Macroglobulinemia Treatment

    SBC: SIRNAX, Inc.            Topic: NCI

    This goal of this project is to develop an innovative process for treating patients with Waldenstr m's macroglobulinemia by suppressing the production of IgM. Waldenstr m's macroglobulinemia is incurable and fatal. The manifestations of this disease that are due to high concentrations of monoclonal IgM are hyperviscosity with headache, fatigue, impaired cognition, confusion, and stroke, ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Real-time bioimpedance based biopsy device

    SBC: RYTEK MEDICAL INC            Topic: NCI

    DESCRIPTION (provided by applicant): Over the last three decades the number of men diagnosed with prostate cancer has increased 85% as a result of new screening and diagnostic tools. However, a significant number of these newly diagnosed men are harboringclinically insignificant disease, which means that they are not likely to die from prostate cancer. A difficul decision facing urologists daily i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a Novel eHealth Application for Oral Systemic Issues during Pregnancy

    SBC: InterVision Media            Topic: NIDCR

    DESCRIPTION (provided by applicant): Oral disease is a silent epidemic because of its prevalence and missed prevention opportunities. Evidence has established connections between oral-systemic etiologies, including the effects of periodontal disease (PD), and a range of health outcomes and co-morbidities across the lifecourse (e.g., adverse pregnancy and birth outcomes; early childhood carries; ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Rapid Screening Assay for Novel Epigenetic Drugs

    SBC: NZUMBE INC            Topic: NIEHS

    DESCRIPTION (provided by applicant): A hallmark of virtually every cancer is aberrant epigenetic silencing of vital genes required for a normal cell cycle and genome stability (e.g. MLH1, BRCA1, VHL, p16, etc.). Loss of expression of these tumor suppressorgenes plays a critical role in cancer formation and growth. Thus, targeting this root cause of cancer has significant potential to treat and pot ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government